USFDA Archives - DelveInsight

USFDA

NASH
Notizia

FDA gives thumbs-up to BalversaThe U.S. FDA has granted approval of Balversa (erdafitinib) to Belgium-based Janssen Pharmaceutica, for the treatment of advanced or metastatic bladder cancer. T...


Sanofi
Gordon and Betty Moore Foundation gives $85M; Omeicos raises; Sanofi signs deal; Lilly grabs

Gordon and Betty Moore Foundation gives USD 85 Million to stop delayed, erroneous diagnosticsThe Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation fo...


Gene Therapy
Is Gene Therapy the Next Cancer Treatment Revolution? 

Gene Therapy is now touted as a new revolution for cancer treatment. If the list of new cancer treatment methodologies is traversed, then the end seems to be farther and farther away. As a sequel t...


BioGen
Business Cocktail

Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion Two major pharmaceutical companies (Merck & Eisai) has entered into a USD 5.76 Billion pact to develop and commerc...


Familial Amyloid Polyneuropathy – An uncommon medical condition

Familial Amyloid Polyneuropathy (also known as transthyretin amyloidosis, TTR, and FAP) is a group of endangering multisystem disorders which are transmitted as an autosomal dominant trait. It is c...


Snippet

Gene therapy is back into play after a decade-long failed deliveries. 2017 was a golden year in gene therapy arena, various companies are aggressively developing gene therapy based treatments targe...


Novo petitions FDA;J&J invests; Xarelto’s trial; Roche’s Tecentriq

Novo petitions FDA to require copies of Victoza to conduct clinical trials With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expir...


Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project

Samsung and Merck launch Remicade biosim at 35% discount After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, an...


Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics ex...

Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications The idiopathic pulmonary fibrosis (IPF) market-share battle between Roche’s Esbriet and Boehringer...


FDA grants accelerated approval to pembrolizumab

The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co.) for adult and pediatric patients with unresectable or metastatic, microsatellite inst...


Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.